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This paper deals with the conducted market research of Russian medicinal preparations used for 
treatment of acute respiratory viral infection in pregnant women. 
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Respiratory diseases today are a major global 
health problem. For example, the incidence of these 
pathologies in the Russian Federation increased by 
12.4% during the period from 2005 to 2011, and the 
temporary disability has increased and now takes the 
first place – 28% of all cases.  The mortality rate, 
according to statistics, in 2009 – 2010 was 56.0 cases 
per 100 thousand people [2].  
In the world, the influenza and acute respiratory 
viral infections (ARVI) cause the main economic 
damage in the structure of infectious respiratory 
diseases. Up to 90% of cases is accounted for acute 
respiratory diseases [1, 7], which is about 30 million 
cases in Russia annually. However, the actual number 
of cases often not seeking medical care 1.5-2 times 
exceeds the official data [8].   
All categories of population are susceptible to 
ARVI, but for some groups of people, they are the 
most dangerous. The main risk group is represented 
by pregnant women, whose incidence structure’s 
leading position is occupied by this pathology [3, 4, 
5, 6]. During pregnancy, there is a physiological 
depression of immunity, so a woman's body becomes 
weak and susceptible to various colds and infectious 
diseases [9]. 
Currently, there is a broad range of medicinal 
drugs (MD) for the treatment of ARVI, but their 
application by pregnant women is limited. Clinical trials 
of the majority of medicinal products (MP) in terms of 
their safe use during pregnancy are either limited, or 
have not been carried out yet. Prescription of medicinal 
treatment is also complicated due to the absence of 
pharmacological standards and formulary lists of 
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medicinal products for the treatment of pregnant 
women with acute respiratory viral infection [10]. 
In connection therewith, it is relevant to study 
the market of medicinal products used for the 
treatment of acute respiratory viral infections in 
pregnant women. 
Objective of the research: to study the market 
of Russian medicinal products used for treatment of 
acute respiratory viral infection in pregnant women. 
Materials and research methods. To conduct 
the study we used official information directories of 
medicinal products: Vidal «Medicines in Russia» 
2014, «Register of medicinal products of Russia» for 
2014-2015; and the «Analyte-Pharmacy» software. 
Methods of research: content analysis, structural, 
comparative, graphic, and segmentation analyses. 
Results and discussion. 
To archive the set objective, we developed the 
research concept consisting of three stages: the 
formation of drug information array; structural analysis 
of the range of medicinal products; and the 
development of macroprofile of the Russian 
pharmaceutical market of medicinal products used in 
treating ARVI in pregnant women. 
During the first stage, we analyzed the official 
sources of information about medicinal products and 
based thereon generated the information array of 
medicinal products for the treatment of ARVI in 
pregnant women. We revealed that the range includes 
503 medicinal drugs, 217 trade names and 67 
international non-proprietary names (INN) 
medicines. 
During the second stage of the study, we 
revealed that the structuring of the range fully on the 
Anatomical Therapeutic Chemical Classification 
(ATC) is not possible, and therefore we added to the 
structure the drugs for ARVI treatment on the 
International Classification of Diseases, 10th edition 
(ICD-10): homeopathic medicines, herbal MD and 
medicinal plant product. 
It was found that seven groups (four – on the 
ATC-3 classification, and three pharmacotherapeutic 
groups) represent the range of the Russian market of 
drugs for the treatment of acute respiratory viral 
infections in pregnant women. Group R «Respiratory 
system» ranks first in the range structure – 293 
medicinal drugs (58.3%). The second is the 
«Medicinal plant product» – 54 MD (10.7%), and the 
third is group N «Nervous system» – 50 MD (9.9%). 
Further, there are herbal drugs – 42 MD (8.3%); 
group L «Antineoplastic and immunomodulating 
agents» – 30 MD (6%); homeopathic drugs – 21 MD 
(4.2%), and group J «Antivirals for systemic use» – 
13 MD (2.6%) (Table 1). 
Studying the MD used for treatment of ARVI in 
pregnant women, we excluded categories of drugs 
such as «contraindicated» and «not recommended».  
The rest of the MD were ranked and grouped. In the 
course of study, we divided the entire range into 6 
subgroups. The leading position is occupied by a 
subgroup of drugs, which can be used only after 
consultation with a doctor or upon doctor’s 
prescription and evaluation of the potential benefit 
for the mother and the risk to the fetus. Drugs of this 
group make a majority – they account for 57.2% (288 
MD) of the total number of MD used during 
pregnancy. The second are medicinal drugs, the use 
of which is prohibited during the 1st trimester of 
pregnancy, and their further use is only possible after 
consulting a doctor and evaluating the risks and 
benefits – 16.1% (81 MD). The third is a group of 
«Use with care» drugs – 14.3% (72 MD). Further, 
there are groups of «Use permitted» – 6% (30 MD), 
«Use possible» – 5% (25 MD), and «Contraindicated 
in the 1st trimester of pregnancy» – 
1.4% (7 MD) (Fig. 1). 
Spichak I.V., Murashko Yu.I. Market research of  russian market of medicinal preparations used 
in therapeutics of acute respiratory viral infection in pregnant women // Сетевой журнал 
«Научный результат». Серия «Медицина и фармация». – Т.1, №4(6), 2015. 
93 
Серия МЕДИЦИНА И ФАРМАЦИЯ  
MEDICINE AND PHARMACY Series 
Table 1 
 The range structure of the medicinal drugs used in treating acute viral respiratory infections in pregnant women, presented in the Russian pharmaceutical market 
No. Classification group 
Number of items 
INN Trade name 
Medicinal preparations 
Total 
incl. 
domestic 
incl. foreign 
incl. new 
Abs. Share, 
% 
Abs. Share, 
% 
Abs. Share, 
% 
Rank Abs. Share, 
% 
Abs. Share, 
% 
Abs. Iо, 
% 
R Respiratory system 
1 R01 Nasal preparations 14  20.9 43 19.8 108 21.5 II 52 48.1 56 51.9 62 57.4 
2 R02 Throat preparations 25 37.3 42 19.4 60 11.9 III 26 43.3 34 56.7 29 48.3 
3 R05 Cough and cold preparations 12 17.9 50 23 125 24.9 I 52 41.6 73 58.4 54 43.2 
Total for group 51 76.1 135 62.2 293 58.3 
N Nervous system 
4 N02 Analgesics 6 9 21 9.7 50 9.9 V 35 70 15 30 18 36 
J Antiinfectives for systemic use 
5 J05 Antiviral preparations for systemic use 3 4.5 3 1.4 13 2.6 IX 8 61.5 5 38.5 10 76.9 
L Antineoplastic and immunomodulating agents 
6 L03 Immunostimulants 7 10.4 14 6.5 30 6 VII 25 83.3 5 16.7 15 50 
Preparations of other groups 
7 Homeopathic medicines - - 19 8.7 21 4.2 VIII 1 4.8 20 95.2 6 28.6 
8 Herbal MD - - 20 9.2 42 8.3 VI 19 45.2 23 54.8 16 38.1 
9 Medicinal plant product - - 5 2.3 54 10.7 IV 54 100 - - 28 51.9 
Total 67 100 217 100 503 100 272 55.3 231 44.7 238 47.8 
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Fig. 1. Segmentation of the MD range by the possibility of using in pregnant women, % 
We conducted the structural analysis of the 
MD range by INN. It was found that the leading 
position is occupied by a group R «Respiratory 
system» – 76.1% (51 MD). Further, there are group 
L preparations «Antineoplastic and 
immunomodulating agents» – 10.74% (7 MD); 
group N «Nervous system» – 9% (6 MD), and 
group J «Antivirals for systemic use» – 4.5% (13 
MD) (Table 3). 
Analysis of the range structure by trade names 
showed that the leading group is also group R 
«Respiratory system» – 62.2% (135 MD TN). 
Further, there are group N «Nervous system» – 
9.7% (21 MD), herbal preparations – 9.2% (20 
MD), Homeopathic preparations – 8.7% (19 MD), 
«Antineoplastic and immunomodulating agents» – 
6.5% (14 MD), «Medicinal plant product» – 
2.3% (5 MD), and «Antivirals for systemic use» – 
1.4% (3 MD). 
During segmentation analysis based on 
production, we found the predominance of the 
domestic drugs – 54.1% (272 MD) over foreign – 
45.9% (231 MD). 
Analysis of offers for drugs of foreign 
manufacturing countries showed that there are 
offers of total 25 foreign countries registered. The 
leading positions among them belong to Germany 
(30.3%), France (7.4%), and India (6.9%). They 
are followed by Great Britain (6.1%), Switzerland 
(5.6%), Italy (5.2%), Slovenia (4.3%), the USA 
(3.5%), Czech Republic (3.5%), and Croatia (3%). 
The rest of the foreign manufacturing countries are 
grouped as «Others» and account for 24.2% (56 
MD). 
The next stage involved segmentation of the 
drugs range by their composition. It was found that 
of the dominant part in the structure belongs to 
single component preparations – 54.9%, while the 
combined MD account for 45.1%. 
The MD segmentation by type of dosage form 
(DF) showed that four groups – liquid, solid, soft, and 
gaseous, represent the range. The liquid MD prevail and 
account for 50%. The leading position among them 
belongs to sprays that are 31.3% (70 MD). Further, 
there are drops – 25.9% (58 MD), syrups – 24.6% (55 
MD,) solutions – 16.5% (37 MD), suspensions – 1.3% 
(3 MD), and emulsions – 0.4% (1 MD). 
The solid MD are the second – 43.4%. The 
leading position among them belongs to tablets – 
65.1% (127 MD). Further, there are powders – 
Use permited 
with care only 
after doctors 
assessment of 
benefits/risks 
57.2% 
contraindicated 
in the 1st 
trimester, use 
with care in 2nd 
and 3rd 
trimesters 16.1% 
Use with care 
14.3 % 
Use permitted 
6% 
Use possible 
5% 
Contraindicated 
in the 1st 
trimester of 
pregnancy 
1.4 % 
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9.2% (18 MD), suppositories – 8.2% (16 MD), 
capsules – 6.2% (12 MD), lyophilizates – 4.6% (9 
MD), pastilles – 3.1 % (6 MD), granules – 2.1% (4 
MD), and pellets – 1.5% (3 MD). 
Soft and gaseous MD are the third – each of 
3.3% (15 MD each). The leading position among 
soft MD belongs to ointment – 86.6% (13 MD), 
then gels and creams – each 6.7% (1 MD each). 
Gaseous MD are represented by aerosols – 3.3% 
(15 MD). 
We analyzed the dynamics of MD registration 
and revealed that the renewal index in all groups of 
studied preparations took on a value of 28.6% to 
76.9% during 2009-2014 in the Russian market, 
and was 47.8% on average. 
It was found that the renewal index was 
maximum for the group J05 «Antiviral 
preparations for systemic use» – 76.9% (10 MD). 
The second is a subgroup R01 «Nasal 
preparations» – 57.4% (62 MD). Further, there are 
medicinal plant product – 51.9% (28 MD), L03 
«Immunostimulators» – 50% (15 MD), R02 
«Throat preparations» – 48.3% (29 MD), R05 
«Cough and cold preparations» – 43.2% (54 LP), 
herbal drugs – 38.1% (16 LP), N02 «Analgesics» – 
36% (18 LP), and homeopathic medicines – 28.6% 
(6 MD). 
Based on these findings, we formed the 
macroprofile of the Russian pharmaceutical market 
of drugs used for the treatment of acute respiratory 
viral infection in pregnant women, which is 
represented mainly by a group R «Respiratory 
system» (58.3%), where the leader by the absolute 
number of the MD is a group R05 «Cough and cold 
preparations» (24.9%). The domestic medicines 
prevail in terms of production (54.1%). The single 
component drugs dominate in the general structure 
of the Russian market (54.9%).  50% of the 
analyzed range is accounted for liquid MD, mostly 
in the form of sprays – 31.3%. The average 
renewal index is 47.8% (Fig. 2).  
R Дыхательная система – RRespiratorysystem. R05 Препараты, применяемые при кашле и простудных заболеваниях – R05 
Coughandcoldpreparations. Отечественные ЛП – DomesticMD. Монопрепараты – Mono-preparation. Жидкие ЛФ – LiquidDF 
Спреи – Sprays Индекс обновления – Renewalindex 
Fig. 2. The macroprofile of the Russian pharmaceutical market of medicinal drugs used in treating acute viral respiratory  
infections in pregnant women, % 
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R Дыхательная 
система 
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Thus, the analysis of the Russian pharmaceutical 
market revealed a significant number of drugs used 
for the treatment of ARVI. However, the range of 
drugs permitted or possible for use in pregnant 
women is only 11% of total range of drugs, which 
requires, in our opinion, the development of 
government decisions on the introduction of drugs 
with a high safety threshold possible for use in 
pregnant women on the Russian pharmaceutical 
market. 
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